Is Amneal Pharmaceuticals, Stock a Good Investment?
Amneal Pharmaceuticals, Investment Advice | AMRX |
- Examine Amneal Pharmaceuticals,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Amneal Pharmaceuticals,'s leadership team and their track record. Good management can help Amneal Pharmaceuticals, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Amneal Pharmaceuticals,'s business and its evolving consumer preferences.
- Compare Amneal Pharmaceuticals,'s performance and market position to its competitors. Analyze how Amneal Pharmaceuticals, is positioned in terms of product offerings, innovation, and market share.
- Check if Amneal Pharmaceuticals, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Amneal Pharmaceuticals,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Amneal Pharmaceuticals, Class stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Amneal Pharmaceuticals, Class is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Amneal Pharmaceuticals, Stock
Researching Amneal Pharmaceuticals,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 53.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 230.5. Amneal Pharmaceuticals, recorded a loss per share of 0.86. The entity had not issued any dividends in recent years.
To determine if Amneal Pharmaceuticals, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Amneal Pharmaceuticals,'s research are outlined below:
| The company reported the previous year's revenue of 2.39 B. Net Loss for the year was (48.72 M) with profit before overhead, payroll, taxes, and interest of 791.46 M. | |
| Amneal Pharmaceuticals, has a strong financial position based on the latest SEC filings | |
| About 53.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Amneal Pharmaceuticals, Inc. Sees Significant Drop in Short Interest |
Amneal Pharmaceuticals, Quarterly Cash And Short Term Investments |
|
Amneal Pharmaceuticals, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Amneal Pharmaceuticals, Class. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amneal Pharmaceuticals,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Amneal Pharmaceuticals,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Amneal Pharmaceuticals,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-07-28 | 2003-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2003-04-30 | 2003-03-31 | -0.08 | -0.07 | 0.01 | 12 | ||
2024-08-09 | 2024-06-30 | 0.14 | 0.16 | 0.02 | 14 | ||
2023-05-05 | 2023-03-31 | 0.1 | 0.12 | 0.02 | 20 | ||
2022-03-01 | 2021-12-31 | 0.2 | 0.18 | -0.02 | 10 | ||
2021-05-07 | 2021-03-31 | 0.18 | 0.2 | 0.02 | 11 | ||
2017-05-10 | 2017-03-31 | 0.13 | 0.11 | -0.02 | 15 | ||
2009-08-04 | 2009-06-30 | 0.03 | 0.05 | 0.02 | 66 |
Know Amneal Pharmaceuticals,'s Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amneal Pharmaceuticals, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amneal Pharmaceuticals, Class backward and forwards among themselves. Amneal Pharmaceuticals,'s institutional investor refers to the entity that pools money to purchase Amneal Pharmaceuticals,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 2.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 M | Blackbarn Capital Partners Lp | 2024-06-30 | 2 M | Fosun International Ltd | 2024-09-30 | 1.7 M | Northern Trust Corp | 2024-09-30 | 1.6 M | Hennessy Advisors, Inc. | 2024-09-30 | 1.6 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | Woodline Partners Lp | 2024-06-30 | 1.3 M | Ubs Group Ag | 2024-06-30 | 21.8 M | Vanguard Group Inc | 2024-09-30 | 14.6 M |
Amneal Pharmaceuticals,'s market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.9 B.Market Cap |
|
Amneal Pharmaceuticals,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | 0.08 | 0.12 | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (4.25) | (4.03) |
Determining Amneal Pharmaceuticals,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Amneal Pharmaceuticals, is a good buy. For example, gross profit margin measures Amneal Pharmaceuticals,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Amneal Pharmaceuticals,'s profitability and make more informed investment decisions.
Amneal Pharmaceuticals,'s Earnings Breakdown by Geography
Please note, the imprecision that can be found in Amneal Pharmaceuticals,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amneal Pharmaceuticals, Class. Check Amneal Pharmaceuticals,'s Beneish M Score to see the likelihood of Amneal Pharmaceuticals,'s management manipulating its earnings.
Evaluate Amneal Pharmaceuticals,'s management efficiency
Amneal Pharmaceuticals, has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.35 | 0.33 | |
| Tangible Book Value Per Share | (8.11) | (8.51) | |
| Enterprise Value Over EBITDA | 7.44 | 7.82 | |
| Price Book Value Ratio | 54.05 | 56.75 | |
| Enterprise Value Multiple | 7.44 | 7.82 | |
| Price Fair Value | 54.05 | 56.75 | |
| Enterprise Value | 3.7 B | 4.4 B |
The strategic initiatives led by Amneal Pharmaceuticals,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.175 |
Basic technical analysis of Amneal Stock
As of the 21st of November, Amneal Pharmaceuticals, shows the Downside Deviation of 1.84, mean deviation of 1.37, and Risk Adjusted Performance of 0.0362. Amneal Pharmaceuticals, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Amneal Pharmaceuticals,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amneal Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amneal Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amneal Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amneal Pharmaceuticals,'s Outstanding Corporate Bonds
Amneal Pharmaceuticals, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Amneal Pharmaceuticals, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Amneal bonds can be classified according to their maturity, which is the date when Amneal Pharmaceuticals, Class has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Amkor Technology 6625 Corp BondUS031652BK50 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Amneal Pharmaceuticals,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Amneal Pharmaceuticals,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0362 | |||
| Market Risk Adjusted Performance | 0.0726 | |||
| Mean Deviation | 1.37 | |||
| Semi Deviation | 1.76 | |||
| Downside Deviation | 1.84 | |||
| Coefficient Of Variation | 2486.68 | |||
| Standard Deviation | 1.82 | |||
| Variance | 3.32 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0626 | |||
| Maximum Drawdown | 11.27 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 3.03 | |||
| Downside Variance | 3.38 | |||
| Semi Variance | 3.08 | |||
| Expected Short fall | (1.40) | |||
| Skewness | 0.0993 | |||
| Kurtosis | 1.77 |
| Risk Adjusted Performance | 0.0362 | |||
| Market Risk Adjusted Performance | 0.0726 | |||
| Mean Deviation | 1.37 | |||
| Semi Deviation | 1.76 | |||
| Downside Deviation | 1.84 | |||
| Coefficient Of Variation | 2486.68 | |||
| Standard Deviation | 1.82 | |||
| Variance | 3.32 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0626 | |||
| Maximum Drawdown | 11.27 | |||
| Value At Risk | (2.38) | |||
| Potential Upside | 3.03 | |||
| Downside Variance | 3.38 | |||
| Semi Variance | 3.08 | |||
| Expected Short fall | (1.40) | |||
| Skewness | 0.0993 | |||
| Kurtosis | 1.77 |
Consider Amneal Pharmaceuticals,'s intraday indicators
Amneal Pharmaceuticals, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Amneal Pharmaceuticals, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 17832.05 | |||
| Daily Balance Of Power | (0.47) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 8.38 | |||
| Day Typical Price | 8.36 | |||
| Price Action Indicator | (0.10) | |||
| Period Momentum Indicator | (0.09) | |||
| Relative Strength Index | 53.69 |
Amneal Pharmaceuticals, Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Amneal Stock media impact
Far too much social signal, news, headlines, and media speculation about Amneal Pharmaceuticals, that are available to investors today. That information is available publicly through Amneal media outlets and privately through word of mouth or via Amneal internal channels. However, regardless of the origin, that massive amount of Amneal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Amneal Pharmaceuticals, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Amneal Pharmaceuticals, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Amneal Pharmaceuticals,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Amneal Pharmaceuticals, alpha.
Amneal Pharmaceuticals, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Amneal Pharmaceuticals, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Amneal Pharmaceuticals, Historical Investor Sentiment
Investor biases related to Amneal Pharmaceuticals,'s public news can be used to forecast risks associated with an investment in Amneal. The trend in average sentiment can be used to explain how an investor holding Amneal can time the market purely based on public headlines and social activities around Amneal Pharmaceuticals, Class. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amneal Pharmaceuticals,'s market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amneal Pharmaceuticals, and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Amneal Pharmaceuticals, news discussions. The higher the estimate score, the more favorable the investor's outlook on Amneal Pharmaceuticals,.
Already Invested in Amneal Pharmaceuticals, Class?
The danger of trading Amneal Pharmaceuticals, Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amneal Pharmaceuticals, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amneal Pharmaceuticals,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amneal Pharmaceuticals, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.